Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080168 | 0.84 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C19CYP3A4KDM4E | |
| SCHEMBL2242512 | 0.76 | ALOX5 (0.47) | ALDH1A1CYP1A2CYP2C19CYP3A4HPGD | |
| SCHEMBL27658638 | 0.75 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2C19CYP3A4NPC1 | |
| SCHEMBL27658739 | 0.75 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2C19CYP3A4HPGD | |
| SCHEMBL2082321 | 0.75 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2C19CYP3A4NPC1 | |
| SCHEMBL2083548 | 0.74 | ALDH1A1 (0.40) | ALDH1A1CYP1A2CYP2C19CYP3A4KDM4E | |
| SCHEMBL2083349 | 0.72 | KMT2A (0.39) | ALDH1A1CYP1A2RAB9AKDM4EALOX5 | |
| SCHEMBL2082568 | 0.71 | MEN1 (0.33) | ALDH1A1HPGDKMT2A | |
| SCHEMBL8626546 | 0.68 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2C19CYP3A4HPGD | |
| SCHEMBL11888072 | 0.67 | KEAP1 (0.32) | ALDH1A1CYP1A2CYP3A4NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854791-B1 | NOVEL THIOPHENE COMPOUND AND PROCESS FOR PRODUCING CAFFENOFURAN OR ANALOGUE THEREOF FROM THE SAME | SAN EI GEN FFI INC (JP) | 2011-07-13 | — | — | EP | disclosed |
| EP-1854791-B1 | NOVEL THIOPHENE COMPOUND AND PROCESS FOR PRODUCING CAFFENOFURAN OR ANALOGUE THEREOF FROM THE SAME | SAN EI GEN FFI INC (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-7897790-B2 | synthetic intermediate that is useful for efficient production of kahweofuran; flavoring; when thiophene compound is reacted in hydrogen atmosphere using transition metal catalyst, cyclization occurs simultaneously with reduction, to produce a 2,3-dihydrothieno[2,3c]furan skeleton in a single step | SAN-EI GEN F.F.I., INC. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897790-B2 | synthetic intermediate that is useful for efficient production of kahweofuran; flavoring; when thiophene compound is reacted in hydrogen atmosphere using transition metal catalyst, cyclization occurs simultaneously with reduction, to produce a 2,3-dihydrothieno[2,3c]furan skeleton in a single step | SAN-EI GEN F.F.I., INC. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897790-B2 | synthetic intermediate that is useful for efficient production of kahweofuran; flavoring; when thiophene compound is reacted in hydrogen atmosphere using transition metal catalyst, cyclization occurs simultaneously with reduction, to produce a 2,3-dihydrothieno[2,3c]furan skeleton in a single step | SAN-EI GEN F.F.I., INC. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20080167481-A1 | Novel Thiophene Compound and Process for Producing Caffenofuran or Analogue Thereof from the Same | SAN EI GEN F.F.I., INC. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167481-A1 | Novel Thiophene Compound and Process for Producing Caffenofuran or Analogue Thereof from the Same | SAN EI GEN F.F.I., INC. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167481-A1 | Novel Thiophene Compound and Process for Producing Caffenofuran or Analogue Thereof from the Same | SAN EI GEN F.F.I., INC. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1854791-A1 | NOVEL THIOPHENE COMPOUND AND PROCESS FOR PRODUCING CAFFENOFURAN OR ANALOGUE THEREOF FROM THE SAME | SAN-EI GEN F.F.I., INC. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167481-A1 | Novel Thiophene Compound and Process for Producing Caffenofuran or Analogue Thereof from the Same | CYP4F3, CBR3, GTF3C4 | ALDH1A1 295/4885CYP1A2 236/4885CYP2C19 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.